Oramed Pharmaceuticals Return on Equity

Oramed Pharmaceuticals (ORMP) currently reports a ROE of 50.9%. That is above the Healthcare sector average of 29.33%. Use the charts on this page to explore Oramed Pharmaceuticals's ROE history and peer comparisons.

Oramed Pharmaceuticals's ROE of 50.9% is higher than the Healthcare sector average of 29.33%. That is roughly 73.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Oramed Pharmaceuticals's current 50.9% should be judged against Healthcare norms (sector average: 29.33%) and against ORMP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 50.9%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Oramed Pharmaceuticals, and consider following ORMP for alerts when major investors trade the stock.

Oramed Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 50.9% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ORMP with unrelated industries.